This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
What are the CE indications for BrainsWay Deep TMS?
BrainsWay has been cleared by the CE for a variety of disorders:
Major Depressive Disorder
Posttraumatic Stress Disorder (PTSD)
Schizophrenia (negative symptoms)
Obsessive Compulsive Disorder (OCD)
BrainsWay has also been cleared by the FDA for treatment resistant depression and Obsessive Compulsive Disorder (OCD) (De Novo).